Comparative Pharmacology
Head-to-head clinical analysis: ARTHROTEC versus JUNIOR STRENGTH IBUPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARTHROTEC versus JUNIOR STRENGTH IBUPROFEN.
ARTHROTEC vs JUNIOR STRENGTH IBUPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Arthrotec is a combination of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and misoprostol, a synthetic prostaglandin E1 analog that protects the gastric mucosa by increasing mucus and bicarbonate secretion, enhancing mucosal blood flow, and promoting epithelial repair.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis involved in pain, inflammation, and fever.
One tablet (diclofenac 50 mg / misoprostol 200 mcg) orally twice daily with food.
Oral: 200-400 mg every 4-6 hours as needed; maximum single dose 400 mg, maximum daily dose 1200 mg for OTC use.
None Documented
None Documented
Diclofenac: ~2 hours (range 1-4 h); misoprostol: 20-40 minutes (acid metabolite 1.5 h). No accumulation with repeated dosing.
Terminal elimination half-life is 2-4 hours in children; prolonged in neonates or hepatic impairment.
Renal: ~95% as metabolites (diclofenac: ~65% as glucuronide conjugates; misoprostol: ~80% as inactive metabolites). Biliary/fecal: <5%.
Renal excretion of conjugated metabolites (approximately 70-90%) and unchanged drug (<10%). Biliary/fecal excretion accounts for <10%.
Category C
Category D/X
NSAID
NSAID